ESMO-话题@MedSci

#ESMO#

215篇内容 | 6237人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1281077, encodeId=c94112810e7fe, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！, objectType=article, longId=737089, objectId=21f9e37089c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21f9e37089c5, replyNumber=0, likeNumber=135, createdTime=2022-08-28, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21f9e37089c5, moduleTitle=ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21f9e37089c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281076, encodeId=ae6f12810e697, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, objectType=article, longId=736795, objectId=5afee36795cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5afee36795cd, replyNumber=0, likeNumber=125, createdTime=2022-08-25, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5afee36795cd, moduleTitle=ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5afee36795cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281075, encodeId=81ea12810e509, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2022ESMO胃肠肿瘤大会精彩内容盘点！, objectType=article, longId=733758, objectId=1b8ce337587c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8ce337587c, replyNumber=0, likeNumber=110, createdTime=2022-07-30, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8ce337587c, moduleTitle=2022ESMO胃肠肿瘤大会精彩内容盘点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8ce337587c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281074, encodeId=73ab12810e402, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2022年7月：ESMO发布ctDNA检测新建议！, objectType=article, longId=733658, objectId=88cbe33658e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88cbe33658e4, replyNumber=0, likeNumber=93, createdTime=2022-07-30, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88cbe33658e4, moduleTitle=2022年7月：ESMO发布ctDNA检测新建议！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88cbe33658e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281073, encodeId=f51312810e3fe, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=【今晚直播】2022年ESMO指南摘要解读, objectType=article, longId=732437, objectId=e16de32437e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e16de32437e6, replyNumber=0, likeNumber=61, createdTime=2022-07-16, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e16de32437e6, moduleTitle=【今晚直播】2022年ESMO指南摘要解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e16de32437e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281072, encodeId=b54212810e243, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302214, objectId=fba0302214dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fba0302214dc, replyNumber=0, likeNumber=123, createdTime=2022-04-03, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fba0302214dc, moduleTitle=2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fba0302214dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281071, encodeId=f7f412810e163, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, objectType=article, longId=302210, objectId=5b43302210bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b43302210bd, replyNumber=0, likeNumber=94, createdTime=2022-04-03, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b43302210bd, moduleTitle=2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b43302210bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281070, encodeId=b40b12810e06f, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）, objectType=article, longId=301725, objectId=d251301e254c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d251301e254c, replyNumber=0, likeNumber=91, createdTime=2022-03-28, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d251301e254c, moduleTitle=ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d251301e254c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281069, encodeId=9cd412810693b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, objectType=article, longId=301718, objectId=f3b0301e18e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b0301e18e1, replyNumber=0, likeNumber=77, createdTime=2022-03-28, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b0301e18e1, moduleTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3b0301e18e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281068, encodeId=d7151281068d0, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, objectType=article, longId=301717, objectId=e006301e1776, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e006301e1776, replyNumber=0, likeNumber=84, createdTime=2022-03-28, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e006301e1776, moduleTitle=ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e006301e1776)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281067, encodeId=0c87128106e94, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, objectType=article, longId=301715, objectId=f4ef301e1547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ef301e1547, replyNumber=0, likeNumber=138, createdTime=2022-03-28, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ef301e1547, moduleTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ef301e1547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281066, encodeId=e9ac128106676, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO OPEN：COVID-19背景下肿瘤学临床试验的新操作方法和地理差异, objectType=article, longId=293039, objectId=28fc2930390b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=28fc2930390b, replyNumber=0, likeNumber=81, createdTime=2021-12-30, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=28fc2930390b, moduleTitle=ESMO OPEN：COVID-19背景下肿瘤学临床试验的新操作方法和地理差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=28fc2930390b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281065, encodeId=8824128106549, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=陈洁：2021年ESMO年会我感兴趣的神经内分泌肿瘤相关摘要, objectType=article, longId=292477, objectId=9e8a2924e7c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e8a2924e7c2, replyNumber=0, likeNumber=0, createdTime=2021-12-23, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e8a2924e7c2, moduleTitle=陈洁：2021年ESMO年会我感兴趣的神经内分泌肿瘤相关摘要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e8a2924e7c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281064, encodeId=12241281064bc, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, objectType=article, longId=221332, objectId=bde422133214, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde422133214, replyNumber=0, likeNumber=83, createdTime=2021-12-01, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde422133214, moduleTitle=ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bde422133214)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281063, encodeId=556c1281063c9, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, objectType=article, longId=221315, objectId=ce4a22131527, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4a22131527, replyNumber=0, likeNumber=99, createdTime=2021-12-01, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4a22131527, moduleTitle=ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4a22131527)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281062, encodeId=41e7128106232, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：在抗肿瘤治疗的癌症患者中，BNT162b2冠状病毒2019信使RNA疫苗接种后体液免疫应答降低, objectType=article, longId=218280, objectId=a9bf2182807d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9bf2182807d, replyNumber=0, likeNumber=83, createdTime=2021-10-10, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9bf2182807d, moduleTitle=ESMO Open：在抗肿瘤治疗的癌症患者中，BNT162b2冠状病毒2019信使RNA疫苗接种后体液免疫应答降低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9bf2182807d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281061, encodeId=786a128106129, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, objectType=article, longId=217452, objectId=1a0421e45297, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0421e45297, replyNumber=0, likeNumber=71, createdTime=2021-09-24, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0421e45297, moduleTitle=ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0421e45297)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281060, encodeId=b0df128106040, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布, objectType=article, longId=217412, objectId=6fdf21e412ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fdf21e412ed, replyNumber=0, likeNumber=100, createdTime=2021-09-23, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fdf21e412ed, moduleTitle=ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fdf21e412ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281059, encodeId=61881281059fb, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO 2021：特瑞普利单抗一线治疗食管癌的Ⅲ期临床研究结果公布，OS高达17个月, objectType=article, longId=217409, objectId=8a7b21e409e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a7b21e409e8, replyNumber=0, likeNumber=89, createdTime=2021-09-23, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a7b21e409e8, moduleTitle=ESMO 2021：特瑞普利单抗一线治疗食管癌的Ⅲ期临床研究结果公布，OS高达17个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a7b21e409e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1281058, encodeId=1fce12810580b, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>, objectTitle=ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性, objectType=article, longId=217042, objectId=d10c21e042bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d10c21e042bc, replyNumber=0, likeNumber=89, createdTime=2021-09-15, rootId=0, userName=zhang92560, userId=7460166, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d10c21e042bc, moduleTitle=ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d10c21e042bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ESMO

2020-05-29

zhang92560

#ESMO#

ESMO Open综述：“神药”光环下的阴影？T-Dxd相关ILD/肺炎发生率超15%！

2022-08-28

zhang92560

#ESMO#

ESMO丨EGFR突变非小细胞肺癌治疗专家共识（2022）

2022-08-25

zhang92560

#ESMO#

2022ESMO胃肠肿瘤大会精彩内容盘点！

2022-07-30

zhang92560

#ESMO#

2022年7月：ESMO发布ctDNA检测新建议！

2022-07-30

zhang92560

#ESMO#

【今晚直播】2022年ESMO指南摘要解读

2022-07-16

zhang92560

#ESMO#

2022年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2022-04-03

zhang92560

#ESMO#

2022 年ESMO专家共识：EGFR突变非小细胞肺癌的治疗

2022-04-03

zhang92560

#ESMO#

ESMO：化疗联合纳武利尤单抗对局部晚期可切除NSCLC治疗，42个月OS率达87.3%（NADIM研究）

2022-03-28

zhang92560

#ESMO#

ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）

2022-03-28

zhang92560

#ESMO#

ESMO：纳武利尤单抗联合化疗新辅助治疗能降低可切除非小细胞肺癌患者EFS风险43%（Checkmate-816研究）

2022-03-28

zhang92560

#ESMO#

ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）

2022-03-28

zhang92560

#ESMO#

ESMO OPEN：COVID-19背景下肿瘤学临床试验的新操作方法和地理差异

2021-12-30

zhang92560

#ESMO#

陈洁：2021年ESMO年会我感兴趣的神经内分泌肿瘤相关摘要

2021-12-23

zhang92560

#ESMO#

ESMO Open：Nab-紫杉醇/吉西他滨和FOLFIRINOX作为一线序贯治疗转移性胰腺癌

2021-12-01

zhang92560

#ESMO#

ESMO Open：紫杉醇联合卡铂的一线方案加用贝伐珠单抗治疗复发性/转移性鼻咽癌

2021-12-01

zhang92560

#ESMO#

ESMO Open：在抗肿瘤治疗的癌症患者中，BNT162b2冠状病毒2019信使RNA疫苗接种后体液免疫应答降低

2021-10-10

zhang92560

#ESMO#

ESMO Open：奥斯替尼联合铂-培美曲塞用于EGFR突变的NSCLC患者的安全性和耐受性

2021-09-24

zhang92560

#ESMO#

ESMO 2021：嘉和生物杰诺单抗治疗中国复发/难治原发性纵隔大B细胞淋巴瘤的Ⅱ期临床研究结果公布

2021-09-23

zhang92560

#ESMO#

ESMO 2021：特瑞普利单抗一线治疗食管癌的Ⅲ期临床研究结果公布，OS高达17个月

2021-09-23

zhang92560

#ESMO#

ESMO Open：Tomuzotuximab vs 西妥昔单抗用作复发/转移性头颈部鳞癌的一线治疗方案的疗效和安全性

2021-09-15